News — Devic disease
Treating Neuromyelitis Optica: Relapse Management and Prevention
AQP4 antibodies autoimmune disorders biologics for NMO corticosteroids for NMO Devic disease eculizumab immunosuppressive therapy inebilizumab long-term NMO care neurologic disability prevention neuromyelitis optica NMO flare treatment NMO relapse management NMO treatment NMO vs MS optic neuritis plasma exchange NMO satralizumab transverse myelitis
Neuromyelitis optica (NMO), also known as Devic’s disease, is a rare autoimmune disorder that targets the optic nerves and spinal cord. Characterized by sudden and often severe relapses, it can cause vision loss, paralysis, and long-term disability if not treated swiftly and appropriately. Unlike multiple sclerosis (MS), NMO is driven by a different mechanism—typically involving antibodies against aquaporin-4 (AQP4), a water channel protein found in the central nervous system.
Managing NMO involves two equally critical fronts: addressing acute relapses as they occur, and implementing long-term strategies to prevent future attacks. With the right approach, many patients can achieve stability and preserve neurological function. This guide breaks down the key principles of treating NMO, from immediate crisis care to proactive prevention that supports quality of life over time.